MetiMedi Co., Ltd. Alternatives & Competitors
12 companies similar to MetiMedi Co., Ltd. — MetiMedi is developing a first-in-class oral immunotherapeutic small molecule in...
Companies similar to MetiMedi Co., Ltd.
Prescient Therapeutics
A clinical stage oncology company developing personalised medicine approaches to cancer; c...
Australia
Carisma Therapeutics
Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors
Philadelphia, United Stat...
ImmunoGenesis, Inc.
Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mech...
Houston, United States
NEOGAP Therapeutics AB
Science for cure.
Stockholm, Sweden
Rival Readout
Competing with MetiMedi Co., Ltd.? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
AltruBio Inc.
Novel Therapeutics for Immunological Diseases
San Francisco, United Sta...
Apexigen
Creating Transformative Immunotherapies for Patients with Cancer
San Carlos, United States
3T Biosciences
3T is an immunotherapy company developing next-generation, transformative therapies for br...
South San Francisco, Unit...
2seventy bio
It’s about time we think smarter and faster than cancer.
Cambridge, United States
Inceptor Bio
Advancing Cell and Gene Therapies to Cure Cancer
Morrisville, United State...
MediMabBio
A biotechnology company that focuses on developing new therapeutic drugs targeting Oncolog...
Korea South
Gracell Biotechnologies
A Member of the AstraZeneca Group
Shanghai, China
Janux Therapeutics
Developing unique immunotherapies that generate tumor-specific immune responses to attack...
San Diego, United States
About MetiMedi Co., Ltd.
MetiMedi Co., Ltd., a pioneering bio pharmaceutical company based in South Korea, is carving a niche in the competitive landscape of immuno-oncology with its innovative approach to cancer therapy. Founded in 2016, the company is developing a first-in-class oral immunotherapeutic small molecule known as METI-101, curren...
Biopharmaceutical, Immuno-oncology, Cancer Therapy, Solid Tumors, Cell Modulator, Metabolic Reprogramming, Immunotherapy, Phase 2 Clinical Studies, Refractory Metastatic Colorectal Cancer, Cell Metabolism Therapy, Chronic Inflammatory Diseases, Novel Therapy, Innovative Treatment, Immune Activation, Tumor Necroptosis
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around MetiMedi Co., Ltd.: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at MetiMedi Co., Ltd. on 18 Mar 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
